DBV Technologies (DBVT) Shares Outstanding (Weighted Average) (2014 - 2026)
DBV Technologies (DBVT) reported Shares Outstanding (Weighted Average) of $428.3 million for Q1 2026, up 317.38% year-over-year from $102.6 million in Q1 2025, and up 400153.11% on a QoQ basis from $107008.0 in Q4 2025.
DBV Technologies (DBVT) has 13 years of Shares Outstanding (Weighted Average) data on file, last reported at $428.3 million in Q1 2026.
- Quarterly Shares Outstanding (Weighted Average) rose 317.38% year-over-year to $428.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $428.3 million (up 317.38% YoY) and the FY2025 annual result came in at $139.6 million, up 43.9% from the prior year.
- Shares Outstanding (Weighted Average) rose to $428.3 million in Q1 2026 per DBVT's latest filing, from $107008.0 in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $428.3 million in Q1 2026 and bottomed at $107008.0 in Q4 2025.
- The 5-year median for Shares Outstanding (Weighted Average) is $54.9 million (2022), against an average of $67.6 million.
- Peak annual rise in Shares Outstanding (Weighted Average) reached 41837.21% in 2025, while the deepest fall reached 99.89% in 2025.
- Tracing DBVT's Shares Outstanding (Weighted Average) over 5 years: stood at $251693.0 in 2022, then dropped by 2.78% to $244693.0 in 2023, then jumped by 39539.62% to $97.0 million in 2024, then slumped by 99.89% to $107008.0 in 2025, then jumped by 400153.11% to $428.3 million in 2026.
- Per Business Quant, the three latest DBVT Shares Outstanding (Weighted Average) figures stand at $428.3 million (Q1 2026), $107008.0 (Q4 2025), and $136.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 428.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 428.30 Mn |
| Dec 31, 2025 | 107,008.00 |
| Sep 30, 2025 | 136.81 Mn |
| Jun 30, 2025 | 195,508.00 |
| Mar 31, 2025 | 102.62 Mn |
| Dec 31, 2024 | 97.00 Mn |
| Sep 30, 2024 | 96.20 Mn |
| Jun 30, 2024 | 244,693.00 |
| Mar 31, 2024 | 244,693.00 |
| Dec 31, 2023 | 244,693.00 |
| Sep 30, 2023 | 251,693.00 |
| Jun 30, 2023 | 251,693.00 |
| Mar 31, 2023 | 93.97 Mn |
| Dec 31, 2022 | 251,693.00 |
| Sep 30, 2022 | 71.78 Mn |
| Jun 30, 2022 | 66.05 Mn |
| Mar 31, 2022 | 54.93 Mn |
| Dec 31, 2021 | 256,693.00 |
| Sep 30, 2021 | 54.91 Mn |
| Mar 31, 2021 | 54.88 Mn |
| Sep 30, 2020 | 54.84 Mn |
| Jun 30, 2020 | 54.88 Mn |
| Mar 31, 2020 | 51.80 Mn |
| Dec 31, 2019 | 7,931.96 |
| Jun 30, 2019 | 2,730.44 |
| Dec 31, 2018 | 8,179.25 |
| Dec 31, 2017 | 2.94 Mn |
| Dec 31, 2016 | 26.61 Mn |
| Dec 31, 2015 | 26.53 Mn |
| Dec 31, 2014 | 23.95 Mn |